We proceeded to test this hypothesis by comparing the survival outcomes of our MYC amp cohort with cases from the MER categorized in the following groups by FISH findings– (1) DLBCL with no MYC abnormalities, (2) DLBCL with MYC rearrangement alone (single hit lymphoma, SHL) and (3) DLBCL with MYC rearrangements and BCL2 or BCL6 rearrangements (DHL/THL). The gene discussed is MYC; the disease is lymphoma.